Morgan Stanley Initiates Diplomat Pharmacy (DPLO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts DPLO Hot Sheet
Price: $4.00 --0%
Rating Summary:
2 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Rating Summary:
2 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Join SI Premium – FREE
Morgan Stanley initiated, upgraded coverage on Diplomat Pharmacy (NYSE: DPLO) with an Overweight rating (prior Equal Weight) and a price target of $41.00.
For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.
Shares of Diplomat Pharmacy closed at $34.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank resumes coverage of Aritzia with Sector Outperform rating, $175 target
- Morgan Stanley Upgrades Tech Mahindra Ltd. (TECHM:IN) to Equalweight
- Enerflex Ltd. (EFX:CN) (EFXT) PT Raised to Cdn$50 at BMO Capital
Create E-mail Alert Related Categories
New Coverage, UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
